Ying-Jhen Su

549 total citations
8 papers, 482 citations indexed

About

Ying-Jhen Su is a scholar working on Molecular Biology, Oncology and Toxicology. According to data from OpenAlex, Ying-Jhen Su has authored 8 papers receiving a total of 482 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Molecular Biology, 4 papers in Oncology and 3 papers in Toxicology. Recurrent topics in Ying-Jhen Su's work include Bioactive Compounds and Antitumor Agents (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Toxin Mechanisms and Immunotoxins (3 papers). Ying-Jhen Su is often cited by papers focused on Bioactive Compounds and Antitumor Agents (3 papers), Wnt/β-catenin signaling in development and cancer (3 papers) and Toxin Mechanisms and Immunotoxins (3 papers). Ying-Jhen Su collaborates with scholars based in Taiwan. Ying-Jhen Su's co-authors include Yi‐Wen Chang, Jia-Lin Lee, Guanying Chen, Szu‐Ting Lin, Chao‐Min Cheng, Yun‐Wei Lin, Jen‐Chung Ko, Shih‐Ci Ciou, Wei‐Hsin Lin and Shin‐Cheh Chen and has published in prestigious journals such as The EMBO Journal, Cancer Research and Biochemical Pharmacology.

In The Last Decade

Ying-Jhen Su

8 papers receiving 479 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ying-Jhen Su Taiwan	8	269	236	90	90	65	8	482
Shih‐Ci Ciou Taiwan	12	239 0.9×	109 0.5×	83 0.9×	64 0.7×	62 1.0×	13	415
Aruljothi Subramaniam United States	7	367 1.4×	205 0.9×	76 0.8×	111 1.2×	101 1.6×	8	653
Fengjun Cao China	16	355 1.3×	127 0.5×	74 0.8×	136 1.5×	28 0.4×	23	589
Min‐Shao Tsai Taiwan	11	224 0.8×	91 0.4×	58 0.6×	42 0.5×	47 0.7×	11	337
Li-Sheng Zheng China	14	343 1.3×	221 0.9×	39 0.4×	144 1.6×	26 0.4×	14	575
Arunkumar Arumugam United States	14	429 1.6×	227 1.0×	63 0.7×	204 2.3×	14 0.2×	27	717
Zhonglin Ni China	5	156 0.6×	137 0.6×	49 0.5×	86 1.0×	28 0.4×	6	410
Kuei-Li Lin Taiwan	12	284 1.1×	119 0.5×	33 0.4×	60 0.7×	44 0.7×	13	503
Sanila H. Sarkar United States	8	549 2.0×	259 1.1×	47 0.5×	220 2.4×	40 0.6×	11	752
Jianyang Hu China	11	354 1.3×	92 0.4×	40 0.4×	100 1.1×	25 0.4×	16	511

Countries citing papers authored by Ying-Jhen Su

Since Specialization

Citations

This map shows the geographic impact of Ying-Jhen Su's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ying-Jhen Su with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ying-Jhen Su more than expected).

Fields of papers citing papers by Ying-Jhen Su

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ying-Jhen Su. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ying-Jhen Su. The network helps show where Ying-Jhen Su may publish in the future.

Co-authorship network of co-authors of Ying-Jhen Su

This figure shows the co-authorship network connecting the top 25 collaborators of Ying-Jhen Su. A scholar is included among the top collaborators of Ying-Jhen Su based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ying-Jhen Su. Ying-Jhen Su is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

8 of 8 papers shown

Chang, Yi‐Wen, Ying-Jhen Su, Michael Hsiao, et al.. (2015). Diverse Targets of β-Catenin during the Epithelial–Mesenchymal Transition Define Cancer Stem Cells and Predict Disease Relapse. Cancer Research. 75(16). 3398–3410. 77 indexed citations

Su, Ying-Jhen, Wei‐Hsin Lin, Yi‐Wen Chang, et al.. (2015). Polarized cell migration induces cancer type-specific CD133/integrin/Src/Akt/GSK3β/β-catenin signaling required for maintenance of cancer stem cell properties. Oncotarget. 6(35). 38029–38045. 48 indexed citations

Su, Ying-Jhen, et al.. (2011). Direct reprogramming of stem cell properties in colon cancer cells by CD44. The EMBO Journal. 30(15). 3186–3199. 150 indexed citations

Ko, Jen‐Chung, Shih‐Ci Ciou, Chao‐Min Cheng, et al.. (2009). Roles of MKK1/2-ERK1/2 and Phosphoinositide 3-Kinase–AKT Signaling Pathways in Erlotinib-Induced Rad51 Suppression and Cytotoxicity in Human Non–Small Cell Lung Cancer Cells. Molecular Cancer Research. 7(8). 1378–1389. 38 indexed citations

Su, Ying-Jhen, et al.. (2009). Role of Rad51 Down-Regulation and Extracellular Signal-Regulated Kinases 1 and 2 Inactivation in Emodin and Mitomycin C-Induced Synergistic Cytotoxicity in Human Non–Small-Cell Lung Cancer Cells. Molecular Pharmacology. 77(4). 633–643. 34 indexed citations

Chen, Ruey-Shyang, Ying-Jhen Su, Wei‐Ting Lee, et al.. (2009). Emodin enhances gefitinib-induced cytotoxicity via Rad51 downregulation and ERK1/2 inactivation. Experimental Cell Research. 315(15). 2658–2672. 26 indexed citations

Ko, Jen‐Chung, Ying-Jhen Su, Szu‐Ting Lin, et al.. (2009). Suppression of ERCC1 and Rad51 expression through ERK1/2 inactivation is essential in emodin-mediated cytotoxicity in human non-small cell lung cancer cells. Biochemical Pharmacology. 79(4). 655–664. 63 indexed citations

Ko, Jen‐Chung, Ying-Jhen Su, Szu‐Ting Lin, et al.. (2009). Emodin enhances cisplatin-induced cytotoxicity via down-regulation of ERCC1 and inactivation of ERK1/2. Lung Cancer. 69(2). 155–164. 46 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact